HeartWare Cancels $930M Deal with Valtech Cardio

| Printer friendly version

HeartWare International, Inc. has announced that it will not longer proceed with its previously announced deal to acquire Valtech Cardio, Ltd.  Valtech is a privately held Israeli company developing transcatheter mitral and tricuspid replacement and repair therapies.  Back in September of 2015, HeartWare announced a definitive agreement to acquire Valtech for a combination of stock and cash estimated to be worth $930 million.  HeartWare’s President and CEO, Doug Godshall, made statements that the new decision to terminate the proposed deal with Valtech was not a reflection on Valtech’s technology:

“While we continue to believe Valtech’s portfolio of mitral and tricuspid interventional tools holds tremendous promise, HeartWare finds itself in a different set of circumstances than when we first entered into the agreement.  Our focus in the coming months will be on returning the MVAD System to the clinic, further enhancing the HVAD System, particularly in light of our plan to submit for the Destination Therapy indication for HVAD in the middle of this year, and progressing our innovative circulatory support pipeline[.]”

The termination follows several months of shareholder disputes and a decline in HeartWare’s stock price. As a result of this termination, HeartWare will be providing Valtech with a $30 million dollar loan.  HeartWare International, Inc. is a publicly traded company focused on miniaturized implantable heart pumps for treating patients from advanced heart failure, having its corporate headquarters in Framingham, Massachusetts.


Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.